Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $11.50 (101.40% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Show:
DateFirmActionRatingPrice TargetDetailsShare
7/8/2014Brean CapitalInitiated CoverageBuy$16.00ViewTweet This Rating  Share This Rating on StockTwits
6/20/2014JPMorgan Chase & Co.Reiterated RatingOverweight$15.00 -> $14.00ViewTweet This Rating  Share This Rating on StockTwits
6/20/2014OppenheimerLower Price TargetOutperform$10.00 -> $8.50ViewTweet This Rating  Share This Rating on StockTwits
5/2/2014MizuhoBoost Price Target$12.00 -> $13.00ViewTweet This Rating  Share This Rating on StockTwits
5/1/2014Cowen and CompanyUpgradeMarket Perform -> OutperformViewTweet This Rating  Share This Rating on StockTwits
5/1/2014JPMorgan Chase & Co.Boost Price Target$9.00 -> $15.00ViewTweet This Rating  Share This Rating on StockTwits
11/8/2013Brean CapitalBoost Price Target$14.00 -> $16.00ViewTweet This Rating  Share This Rating on StockTwits
8/9/2013Bank of AmericaDowngradeBuy -> Neutral$13.00 -> $6.00ViewTweet This Rating  Share This Rating on StockTwits
8/9/2013OppenheimerLower Price TargetOutperform$12.00 -> $10.00ViewTweet This Rating  Share This Rating on StockTwits
8/8/2013Cowen and CompanyDowngradeOutperform -> Market PerformViewTweet This Rating  Share This Rating on StockTwits
6/24/2013MizuhoInitiated CoverageBuy$12.00ViewTweet This Rating  Share This Rating on StockTwits
11/9/2012GuggenheimInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
9/27/2012Brean CapitalInitiated CoverageBuy$12.00ViewTweet This Rating  Share This Rating on StockTwits
8/31/2012Bank of AmericaInitiated CoverageBuy$13.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2012 forward)